Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
Portfolio Pulse from
Clearside Biomedical's Asia-Pacific partner, Arctic Vision, has received approval for the suprachoroidal treatment ARCATUS® (known as XIPERE® in the U.S.) for uveitic macular edema in Australia and Singapore. This marks the first global approval of a suprachoroidal therapy.
January 22, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clearside Biomedical's partner, Arctic Vision, has received regulatory approval for ARCATUS® in Australia and Singapore, marking a significant milestone for the company as it expands its suprachoroidal therapy globally.
The approval of ARCATUS® in Australia and Singapore by Clearside's partner Arctic Vision is a significant regulatory milestone. It expands the market for Clearside's suprachoroidal therapy, potentially increasing revenue and enhancing the company's reputation in the biotech industry.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80